These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29803939)

  • 21. Heparan sulfate proteoglycans and heparin regulate melanoma cell functions.
    Nikitovic D; Mytilinaiou M; Berdiaki A; Karamanos NK; Tzanakakis GN
    Biochim Biophys Acta; 2014 Aug; 1840(8):2471-81. PubMed ID: 24486410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparan Sulfate Proteoglycans May Promote or Inhibit Cancer Progression by Interacting with Integrins and Affecting Cell Migration.
    Soares MA; Teixeira FC; Fontes M; Arêas AL; Leal MG; Pavão MS; Stelling MP
    Biomed Res Int; 2015; 2015():453801. PubMed ID: 26558271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of synthesis of a large heparan sulfate proteoglycan, perlecan, by thrombin in cultured human coronary smooth muscle cells.
    Yamamoto C; Wakata T; Fujiwara Y; Kaji T
    Biochim Biophys Acta; 2005 Feb; 1722(1):92-102. PubMed ID: 15716125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The multifaceted roles of perlecan in fibrosis.
    Lord MS; Tang F; Rnjak-Kovacina J; Smith JGW; Melrose J; Whitelock JM
    Matrix Biol; 2018 Aug; 68-69():150-166. PubMed ID: 29475023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparan sulfate proteoglycan as a cell-surface endocytosis receptor.
    Christianson HC; Belting M
    Matrix Biol; 2014 Apr; 35():51-5. PubMed ID: 24145152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparan sulfate proteoglycan as a plasma membrane carrier.
    Belting M
    Trends Biochem Sci; 2003 Mar; 28(3):145-51. PubMed ID: 12633994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal heparan sulfate proteoglycans modulate fibroblast growth factor 2 signaling in experimental chronic transplant dysfunction.
    Katta K; Boersema M; Adepu S; Rienstra H; Celie JWAM; Mencke R; Molema G; van Goor H; Berden JHM; Navis G; Hillebrands JL; van den Born J
    Am J Pathol; 2013 Nov; 183(5):1571-1584. PubMed ID: 24035513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparan sulfate proteoglycans: coordinators of multiple signaling pathways during chondrogenesis.
    Kirn-Safran CB; Gomes RR; Brown AJ; Carson DD
    Birth Defects Res C Embryo Today; 2004 Mar; 72(1):69-88. PubMed ID: 15054905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparan sulfate proteoglycans in invasion and metastasis.
    Sanderson RD
    Semin Cell Dev Biol; 2001 Apr; 12(2):89-98. PubMed ID: 11292374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear translocation of heparan sulfate proteoglycans and their functional significance.
    Kovalszky I; Hjerpe A; Dobra K
    Biochim Biophys Acta; 2014 Aug; 1840(8):2491-7. PubMed ID: 24780644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins.
    Foley EM; Esko JD
    Prog Mol Biol Transl Sci; 2010; 93():213-33. PubMed ID: 20807647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Syndecan-3 and perlecan are differentially expressed by progenitors and mature oligodendrocytes and accumulate in the extracellular matrix.
    Winkler S; Stahl RC; Carey DJ; Bansal R
    J Neurosci Res; 2002 Aug; 69(4):477-87. PubMed ID: 12210841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues.
    Platt JL; Wrenshall LE; Johnson GB; Cascalho M
    Adv Exp Med Biol; 2015; 865():123-40. PubMed ID: 26306447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding.
    Herndon ME; Stipp CS; Lander AD
    Glycobiology; 1999 Feb; 9(2):143-55. PubMed ID: 9949192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced perlecan expression and accumulation in human carotid atherosclerotic lesions.
    Tran PK; Agardh HE; Tran-Lundmark K; Ekstrand J; Roy J; Henderson B; Gabrielsen A; Hansson GK; Swedenborg J; Paulsson-Berne G; Hedin U
    Atherosclerosis; 2007 Feb; 190(2):264-70. PubMed ID: 16620836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developmental roles of heparan sulfate proteoglycans: a comparative review in Drosophila, mouse and human.
    Princivalle M; de Agostini A
    Int J Dev Biol; 2002 May; 46(3):267-78. PubMed ID: 12068947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin releasable and nonreleasable forms of heparan sulfate proteoglycan are found on the surfaces of cultured porcine aortic endothelial cells.
    Lowe-Krentz LJ; Thompson K; Patton WA
    Mol Cell Biochem; 1992 Jan; 109(1):51-60. PubMed ID: 1614420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Release of glomerular heparan-35SO4 proteoglycan by heparin from glomeruli of streptozocin-induced diabetic rats.
    Klein DJ; Oegema TR; Brown DM
    Diabetes; 1989 Jan; 38(1):130-9. PubMed ID: 2521210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism.
    Williams KJ; Fuki IV
    Curr Opin Lipidol; 1997 Oct; 8(5):253-62. PubMed ID: 9335948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diverse cell signaling events modulated by perlecan.
    Whitelock JM; Melrose J; Iozzo RV
    Biochemistry; 2008 Oct; 47(43):11174-83. PubMed ID: 18826258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.